News & Events

Dr Le on Innovations and Future Directions for KRAS Inhibition in NSCLC

Dr Le on Innovations and Future Directions for KRAS Inhibition in NSCLC

Moffitt Cancer Center Studies Highlight Strategies to Overcome Drug Resistance in KRAS G12C-Mutant NSCLC

Moffitt Cancer Center Studies Highlight Strategies to Overcome Drug Resistance in KRAS G12C-Mutant NSCLC

STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status

STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status

Elironrasib Active in KRAS G12C–Resistant NSCLC

Elironrasib Active in KRAS G12C–Resistant NSCLC

Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation

Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation

Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation

Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation

Findings on Non-Small Cell Lung Cancer Reported by Researchers at University of Michigan (A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell...

Findings on Non-Small Cell Lung Cancer Reported by Researchers at University of Michigan (A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell...

Elironrasib May Overcome Resistance to Prior KRAS G12C Inhibition in Non-small Cell Lung Cancer

Elironrasib May Overcome Resistance to Prior KRAS G12C Inhibition in Non-small Cell Lung Cancer

Elironrasib may overcome resistance to prior KRAS G12C inhibition in non-small cell lung cancer

Elironrasib may overcome resistance to prior KRAS G12C inhibition in non-small cell lung cancer